Get to know our clinical trials

Trial of relatlimab plus nivolumab in pediatric and young adult participants with relapsed or refractory classical Hodgkin's lymphoma and non-Hodgkin's lymphoma.

THE OBJECTIVE OF THIS STUDY IS TO OBTAIN INFORMATION ON THE SAFETY AND EFFICACY OF NIVOLUMAB AND RELATLIMAB IN PARTICIPANTS WITH CLASSICAL HODGKIN'S LYMPHOMA AND RELAPSED/RECURRENT OR REFRACTORY NON-HODGKIN'S LYMPHOMA.

Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE I/II STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF RELATLIMAB PLUS NIVOLUMAB IN PEDIATRIC AND YOUNG ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA AND NON-HODGKIN'S LYMPHOMA. IMMUNOTHERAPY
  • Code EudraCT: 2021-000493-29
  • Protocol number: CA224-069
  • Promoter: Bristol Myers Squibb

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.